Scientific News
-
How to Manage Thalassaemia During Pregnancy: Expert Advice from the BSH
A comprehensive multidisciplinary approach is essential for managing conception and pregnancy in patients with a variety of medical conditions, including obesity, diabetes, and hypertension. Thalassaemia, an inherited blood disorder that…
Read More » -
High Survival Rates for SCD Patients with Groundbreaking Transplant Approach
A bone marrow transplant strategy that avoids high-dose chemotherapy to prevent an immune reaction against donor stem cells has demonstrated high rates of event-free and overall survival in sickle cell…
Read More » -
Oxbryta Shows Promise in Reducing Cell Sickling in Pediatric SCD Patients
In a promising leap forward for pediatric sickle cell disease (SCD) treatment, the oral medication Oxbryta (voxelotor) has been shown to reduce the sickling and disintegration of red blood cells…
Read More » -
Recent Study Links Transfusion-Dependent Thalassaemia to Adverse Maternal, Neonatal Outcomes
A meta-analysis of 15 studies found that pregnant women with β-thalassaemia major and β-thalassaemia intermedia were at greater risk of heart failure, venous thromboembolism, death, and other adverse neonatal and…
Read More » -
Pain Impact and Management in Individuals With Transfusion-Dependent Thalassaemia
Over the last several decades, there has been significant progress in addressing the main symptoms and related health issues of people with transfusion-dependent thalassemia (TDT). Yet, the problem of pain…
Read More » -
Chinese Base Editing Therapy ‘Clinically Cured’ Patient with β-Thalassaemia, Researchers Say
Shanghai-based biotech company CorrectSequence Therapeutics, in collaboration with Guangxi Medical University, has achieved a significant clinical milestone by successfully treating a young patient with transfusion-dependent β-thalassaemia using their base editing…
Read More » -
CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK
Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. The therapy, developed by…
Read More » -
Imatinib’s Impact on Reducing Painful Episodes in Sickle Cell Disease
Currently, hydroxyurea (HU) is the only FDA-approved drug highly recommended for treating sickle cell anemia. However, its efficiency varies among patients with sickle cell disease for unknown reasons. Given the…
Read More » -
Corticosteroid Use in Pregnant Women with SCD Doubles Risk of Severe VOCs
According to a French study, corticosteroids used during pregnancy are a risk factor for more severe vaso-occlusive crises (VOCs) in women with sickle cell disease (SCD). This risk was especially…
Read More » -
The Hidden Dangers of Sickle Cell Trait: Unraveling the Risk for Complications
Worldwide, it is estimated that there are 300 million people with sickle cell trait and one-third of this number are in sub-Saharan Africa. With these staggering figures, sickle cell disease…
Read More »